Immunoassay Market Size, Share, Product Innovations, and Future Opportunities 2034
Immunoassay Market Size, Share, Product Innovations, and Future Opportunities 2034
Immunoassays are laboratory techniques used to detect and measure specific substances, including antibodies, antigens, hormones, proteins, drugs, and disease-related biomarkers. These tests use the specific binding properties of antibodies to identify target substances in biological samples. They are widely applied in clinical diagnostics, infectious disease screening, endocrinology, cardiology, oncology, autoimmune disease testing, reproductive health, and pharmaceutical research.
According to Fortune Business Insights, the global immunoassay market size was valued at USD 26.80 billion in 2025. The market is projected to grow from USD 28.81 billion in 2026 to USD 51.80 billion by 2034, exhibiting a CAGR of 7.6% during the forecast period. North America dominated the immunoassay market with a market share of 33.76% in 2025.
Hoffmann-La Roche Ltd. (Switzerland)
Abbott (U.S.)
Siemens Healthineers AG (Germany)
Beckman Coulter, Inc. (U.S.)
BIOMÉRIEUX (France)
QuidelOrtho Corporation (U.S.)
DiaSorin S.p.A. (Italy)
Revvity (U.S.)
Thermo Fisher Scientific Inc. (U.S.)
Bio-Rad Laboratories, Inc. (U.S.)
Increasing Adoption of Biomarker-Based Diagnosis: The growing use of biomarkers in disease diagnosis and monitoring is a major factor supporting market expansion. Immunoassays help healthcare professionals detect and monitor infectious diseases, thyroid disorders, cardiac conditions, cancer markers, autoimmune diseases, and neurological conditions. Their ability to support repeated testing and clinical monitoring makes them valuable across hospitals, diagnostic laboratories, and outpatient facilities.
Growing Demand for Automated Laboratory Testing: Healthcare facilities are increasingly adopting automated and high-throughput immunoassay platforms to manage rising diagnostic workloads. Automated systems streamline sample handling, reagent dispensing, detection, and result interpretation. These capabilities help laboratories improve productivity, reduce manual intervention, and support consistent testing processes.
Expansion of Point-of-Care and Home-Based Testing: The development of convenient diagnostic solutions is creating opportunities for immunoassay manufacturers. Point-of-care testing can support faster clinical decisions, while home-based testing offers additional convenience for selected diagnostic applications. These approaches are contributing to the expansion of immunoassay use beyond conventional laboratory settings.
High Instrument and Reagent Costs: The substantial investment required for analyzers, proprietary reagents, calibrators, maintenance, and trained personnel can restrict adoption, particularly among smaller laboratories and healthcare facilities in resource-limited markets. Regulatory requirements and the need for quality-control procedures also increase operational expenses.
Assay Interference and Standardization Challenges: Cross-reactivity, sample-related interference, calibration differences, and limited standardization can affect the comparability of results across testing platforms. Manufacturers and laboratories must maintain analytical accuracy and conduct appropriate validation and quality-control procedures to support reliable testing.
The global immunoassay market includes established diagnostic and life sciences companies with broad product portfolios and strong market presence. Thermo Fisher Scientific Inc., Hoffmann-La Roche Ltd., Abbott, Beckman Coulter, Inc., and Bio-Rad Laboratories, Inc. held leading positions in 2025, supported by their established brands and extensive immunoassay offerings.
Market participants are focusing on product development, automation, strategic collaborations, acquisitions, and expanded research and development activities. Companies are also introducing specialized assays and advanced analyzers to address demand across infectious disease testing, oncology, endocrinology, and neurological diagnostics. These initiatives are helping providers strengthen their product portfolios and expand their presence in global diagnostic markets.
By Product Type (Instruments, Reagents & Kits, and Consumables & Accessories)
By Detection Technology (Chemiluminescence & Electrochemiluminescence, Colorimetric, Fluorescence, and Radioimmunoassays),
By Application (Clinical Diagnostics [Infectious Diseases, Endocrinology, Cardiac Disorders, and Oncology] and Non-Clinical Applications [Drug Discovery])
By End-User (Hospitals & Clinics, Independent & Reference Laboratories, Pharmaceutical & Biotechnology Companies, and Academic & Research Institutes)
Explore the full research report with detailed insights and TOC: https://www.fortunebusinessinsights.com/immunoassay-market-104464
North America: North America dominated the global immunoassay market with a 33.76% share in 2025. The U.S. market is anticipated to reach USD 8.89 billion in 2026. Advanced laboratory infrastructure, adoption of automated analyzers, and substantial diagnostic testing volumes support regional demand.
Asia Pacific: The Asia Pacific market is projected to reach approximately USD 9.74 billion in 2026, making it an important regional market. Increasing diagnostic requirements, a growing geriatric population, and improvements in healthcare infrastructure support market development. China, Japan, and India are among the key country markets.
Europe: Europe is projected to reach USD 7.56 billion in 2026, with a growth rate of 6.6% during the forecast period. Established laboratory networks, automated analyzer installations, and regional initiatives supporting diagnostic standardization contribute to market growth.
Latin America: The Latin America market is estimated to reach approximately USD 0.94 billion in 2026. Increasing healthcare spending and efforts to expand diagnostic access are supporting regional development.
The future of the immunoassay market will be shaped by advancements in automated testing, biomarker-based diagnosis, and specialized clinical applications. The integration of artificial intelligence into laboratory platforms is expected to support quality control, result interpretation, predictive maintenance, and improved workflow management. Growing interest in blood-based neurological biomarkers also presents opportunities for manufacturers. High-sensitivity immunoassays may support the measurement of selected biomarkers associated with neurological conditions, creating additional applications in routine laboratory testing. Furthermore, expanding point-of-care testing and continued development of specialized assays are expected to broaden the market's scope.
Curious About Japan’s Market? Explore the Latest -Immunoassay Market- Insights